primary hepatocellular carcinoma
Conditions
Interventions
Gold Standard:Pathological examination
Index test:A machine learning model based on the MRI multi-sequence radiomics features and clinical features before lenvatinib combined with immunotherapy and interventional therapy
Sponsors
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. The patient was clinically or pathologically diagnosed with hepatocellular carcinoma and was evaluated as unresectable hepatocellular carcinoma; 2. The patient has received at least one cycle of lenvatinib combined with immunotherapy and interventional therapy, and have not previously received other anticancer treatments; 3. There were MRI examination data with Gd-EOB-DTPA enhancement within one month before treatment; 4. The patient had at least one target lesion available for assessing tumor response to treatment according to modified Response Evaluation Criteria in Solid Tumors;
Exclusion criteria
Exclusion criteria: 1. Presence of other primary malignant tumors; 2. The patient with severe concomitant cardiac, pulmonary, hepatic, renal, or other functional impairments was assessed as unable to tolerate the combination therapy regimen; 3. Concurrent receipt of other anticancer therapies;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The predictive performance and clinical application value of multi-sequence MRI machine learning models;Sensitivity;Specificity; | — |
Secondary
| Measure | Time frame |
|---|---|
| Survival outcomes, including progression-free survival (PFS) and overall survival (OS);Pathological complete response; | — |
Countries
China
Contacts
Public ContactChangzhen Shang
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Outcome results
None listed